Sangamo kept at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Sangamo BioSciences, Inc. at market outperform on news of promising preclinical data on CCR5-ZFN for HIV. While more preclinical studies in animals will be necessary and given the complicated process of ex vivo cell enrichment, Duncan believes the studies signal a potentially effective approach to fighting HIV infection. Shares of the Richmond, Calif.-based pharmaceutical company were up 3 cents, or 0.56%, at $5.41. (Nasdaq: SGMO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.